Analyst firms · Robert W. Baird · QGEN
Robert W. Baird QGEN price target and rating history
Qiagen N.V. (QGEN) · Health Care
Robert W. Baird rates Qiagen N.V. (QGEN) Outperform with a $43 price target, as of its latest action on Apr 29, 2026. It has published 3 rating actions on QGEN since September 2023, including 1 upgrade and 1 downgrade. Across 8 firms with a QGEN price target in the last 12 months, the median target is $46.25. Robert W. Baird's $43 is 7% below that.
- Current rating
- Outperform
- Price target
- $43
- Median target, all firms
- $46.25
- Actions on QGEN
- 3
Robert W. Baird price target on QGEN
Every Robert W. Baird rating on QGEN
- Apr 29, 2026
- Feb 19, 2025
- Sep 12, 2023
How other firms rate QGEN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $55 | Oct 6, 2026 |
| UBS | Neutral | $47 | Sep 9, 2026 |
| Berenberg | Hold | $45.50 | Jul 14, 2026 |
| Kepler Cheuvreux | Hold | $38.60 | Jun 25, 2026 |
| Morgan Stanley | Overweight | $42 | Jun 23, 2026 |
| Robert W. Baird | Outperform | $43 | Apr 29, 2026 |
| Deutsche Bank | Buy | $54 | Mar 13, 2026 |
| Citigroup | Neutral | $50 | Dec 11, 2025 |
Questions about Robert W. Baird and QGEN
- What is Robert W. Baird's price target for QGEN?
- Robert W. Baird's latest stated price target for Qiagen N.V. (QGEN) is $43, from its action on Apr 29, 2026.
- What is Robert W. Baird's rating on QGEN?
- Robert W. Baird rates QGEN Outperform, a bullish rating, as of Apr 29, 2026.
- When did Robert W. Baird last change its view on QGEN?
- On Apr 29, 2026, Robert W. Baird upgrades to Outperform from Neutral, price target $43.
- How does Robert W. Baird's QGEN target compare with other analysts?
- Across 8 firms with a QGEN price target in the last 12 months, the median target is $46.25. Robert W. Baird's $43 is 7% below that.
More QGEN rating histories
All Robert W. Baird ratingsQGEN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.